Centre for Human Drug Research’s Post

Preclina is a global leading non-clinical CRO that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We're strengthening our leadership in immunological research by broadening our portfolio with sophisticated humanized mouse models, specifically optimized for oncology drug development. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. Meet Preclina Inc. at their booth @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

New out in #NatureMedicine Nature Portfolio: A single-cell ex vivo screening of repurposable drugs in #Glioblastoma and #MachineLearning of drug–target networks show that anti-tumor neuroactive drugs converge on the AP-1/BTG pathway, based on which prediction models and experimental in vivo and in silico validation identify the #AntiDepressant #Vortioxetine as a potential therapeutic agent; by Sohyon Lee, Tobias Weiss, Berend Snijder, et al. https://lnkd.in/ev5E6Sa4

Continued strong news from Ovid Therapeutics on OV329, a rationally designed, next-generation GABA-AT inhibitor for the potential treatment of drug-resistant #seizures, developed in the laboratories of Northwestern University Professor Richard Silverman. Ovid publishes preclinical work that finds OV329 appears to increase GABA levels in animal brains through both phasic and tonic inhibition, which indicates that it may have the potential to deliver sustained anti-seizure properties at very low doses in humans. https://lnkd.in/gZrnEdeN News on the compound was originally highlighted in Science Magazine - https://lnkd.in/g4xxqfbF #biopharmaceuticals, #therapeutics, #epilepsy, #brainconditions, #biotech Chemistry of Life Processes Institute, Northwestern University - Weinberg College of Arts and Sciences, Northwestern University Department of Chemistry

Did you hear Enveric Biosciences, Inc. presented compelling preclinical data on their lead compound, EB-003, at the 7th Neuropsychiatric Drug Summit? EB-003 is a neuroplastogenic, non-hallucinogenic DMT analog designed to provide therapeutic benefits for anxiety and depression without the typical psychedelic side effects. Their research demonstrates its potential to reduce anxiety and depression in preclinical models while maintaining optimal brain exposure levels after oral dosing. “EB-003’s unique profile and promising data set it apart from other DMT-based drugs in development, making it a key value driver for Enveric and our shareholders,” shared Joseph Tucker, Ph.D., CEO of Enveric. Read more about their research! 🔗 https://buff.ly/3N9mMnb $ENVB #NeuropsychiatricSummit #MentalHealthInnovation #EB003 #PsychedelicResearch #FutureOfMedicine #DrugDevelopment #Neuroplasticity

Breaking boundaries in rare neurological conditions! 🧠 #Ipsen and #SkyhawkTherapeutics unite in an exclusive global collaboration to pioneer small molecule drugs targeting RNA. Ipsen's monumental commitment of up to $1.8 billion reflects their unwavering dedication to innovation. With Skyhawk's cutting-edge RNA targeting technology and Ipsen's expertise in movement disorders, this partnership heralds a new era of treatment advancement. #MedicalInnovation #Neurology #Healthcare #RNA #RASLifeScienceSolutions

We are excited to announce Rejuvenate Biomed as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting. Rejuvenate Biomed is a clinical-stage biotechnology company developing therapeutics that target the root causes of age-related diseases. Utilizing two clinically validated proprietary drug discovery platforms, the AI-enabled in silico CombinAgeTM and in vivo CelegAgeTM, Rejuvenate Biomed has built a pipeline of five unique combination drugs targeting different age-related diseases, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative indications. Its lead Phase 2-ready asset, RJx-01, has already demonstrated significant potential in treating sarcopenia. The company’s disease agnostic drug discovery platforms continue to provide insight into future therapeutics, driving pipeline growth and potential partnerships. Based in Belgium, Rejuvenate Biomed is dedicated to promoting healthy aging. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024. More info at agingpharma.org https://lnkd.in/g3VR_xqU #ARDD2024 #DrugDiscovery #AgingResearch

Happy to share our new publication in Clinical Pharmacology & Therapeutics: Kiesel B et al. Jun 2024. Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis. https://lnkd.in/eRcn5bd4

𝗜𝗟-𝟭𝟭 is an attractive target in drug discovery due to its potential pro-inflammatory and pro-fibrotic roles in pulmonary, hepatic, cardiovascular, renal, and intestinal diseases, including oncogenesis. Despite its therapeutic potential, challenges such as limited tissue penetration and off-target effects have hindered the development of effective inhibitors. Through 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗽𝗵𝗮𝗴𝗲 𝗱𝗶𝘀𝗽𝗹𝗮𝘆 techniques, IRBM, in collaboration with Takeda scientists, identified a 𝗰𝘆𝗰𝗹𝗶𝗰 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝗹𝗲𝗮𝗱 able to 𝗶𝗻𝗵𝗶𝗯𝗶𝘁 𝘁𝗵𝗲 𝗜𝗟-𝟭𝟭/𝗜𝗟-𝟭𝟭𝗥α 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻, which represents a major step forward in the development of 𝗽𝗲𝗽𝘁𝗶𝗱𝗲-𝗯𝗮𝘀𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 of the IL-11-mediated signaling pathway. Key characteristics of the lead compound include: // 𝗡𝗮𝗻𝗼𝗺𝗼𝗹𝗮𝗿 𝗮𝗳𝗳𝗶𝗻𝗶𝘁𝘆 𝗮𝗻𝗱 𝗽𝗼𝘁𝗲𝗻𝗰𝘆: Achieving a KD of 140 nM and Ki of 180 nM, surpassing prior inhibitors by 70-fold // 𝗘𝘅𝗰𝗲𝗽𝘁𝗶𝗼𝗻𝗮𝗹 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆: Successfully accomplished through a phage display biopanning campaign strategy designed to disrupt IL-11/IL-11Rα dimerization without off-target effects. // 𝗟𝗼𝘄𝗲𝗿 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝘄𝗲𝗶𝗴𝗵𝘁: Facilitating superior tissue penetration compared to traditional antibody-based therapies This research not only highlights the power of phage display in generating highly specific peptide inhibitors but also supports the collaboration’s objective to advance potential therapies targeting fibrosis, inflammation, and cancer. Congrats to all the brilliant scientists involved in this work, especially the lead author Sam Lear and our Display Technologies stars here at IRBM: Rosalba Tafi, Valentina A. Di Biasio, Claudia Dall'Armi, and Anna Demartis … 🔬We’re IRBM, a CRO partner specializing in early-stage drug discovery, focused on supporting preclinical research across various therapeutic areas. ➕ Follow us for practical insights into advancing drug discovery, updates on our capabilities, and the latest trends in preclinical innovation. #scientificpublication #scientificexcellence #drugdiscovery #IRBM

🚀 Exciting Progress in Gene Editing for Rare Diseases: Intellia's RMAT Designation 🧬 Intellia Therapeutics, Inc. has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its investigational in vivo genome-editing candidate, Nexiguran ziclumeran (nex-z), also known as NTLA-2001. This designation is a major milestone in the treatment of hereditary transthyretin amyloidosis (ATTR) with polyneuropathy (ATTRv-PN). Key Highlights: RMAT designation allows for closer FDA collaboration, paving the way for accelerated approval and priority review of the biologics license application (BLA). Interim Phase I data shows that nex-z results in rapid, deep, and durable TTR reduction, potentially halting or even reversing the disease. Intellia has partnered with Regeneron Pharmaceuticals (REGN) on the development of nex-z, with the first pivotal Phase III study, MAGNITUDE-2, set to enroll patients by the end of 2024. This breakthrough brings hope to patients with ATTRv-PN and ATTR amyloidosis with cardiomyopathy (ATTRv-CM), both of which are currently being explored in ongoing clinical trials. Despite a challenging year for Intellia's stock, the RMAT designation is a step toward the potential transformational impact of gene-editing technologies on rare diseases. Looking forward to seeing how nex-z continues to evolve! #Biotech #GeneEditing #FDA #RMAT #Innovation #Healthcare #MedicalResearch #Pharma #RareDiseases #Intellia #Regeneron https://lnkd.in/gAChnHS5

Teva Pharmaceuticals is doubling down on innovation with a biotech approach, pushing key drugs through the clinic faster than ever. Their R&D focus, led by Eric A. Hughes, MD, PhD, has been revolutionizing clinical trials and driving key pipeline advancements in neuroscience and immunology. 💡 Key Insights - Accelerated trials for drugs like long-acting olanzapine and duvakitug in IBD. - Focus on innovative medicines while balancing Teva’s generics history.    ❓ Questions to Consider - Can Teva’s biotech-inspired approach redefine speed in clinical trial execution? - How might this shift impact their competitive edge in neuroscience and immunology? #PharmaInnovation #R&D #BiotechTransformation #Teva